{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:38:15Z","timestamp":1788143895810,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.bcp.2023.115862","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T15:37:35Z","timestamp":1697557055000},"page":"115862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Biktarvy for the treatment of HIV infection: Progress and prospects"],"prefix":"10.1016","volume":"217","author":[{"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6479","key":"10.1016\/j.bcp.2023.115862_b0005","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1126\/science.aay8015","article-title":"Structural basis for strand-transfer inhibitor binding to HIV intasomes","volume":"367","author":"Passos","year":"2020","journal-title":"Science"},{"issue":"6479","key":"10.1016\/j.bcp.2023.115862_b0010","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.aay4919","article-title":"Structural basis of second-generation HIV integrase inhibitor action and viral resistance","volume":"367","author":"Cook","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 Recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"J. Am. Med. Assoc."},{"issue":"8","key":"10.1016\/j.bcp.2023.115862_b0020","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/hiv.13268","article-title":"Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021","volume":"23","author":"Ryom","year":"2022","journal-title":"HIV Med.."},{"issue":"11","key":"10.1016\/j.bcp.2023.115862_b0025","doi-asserted-by":"crossref","first-page":"e25970","DOI":"10.1002\/jia2.25970","article-title":"Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review","volume":"25","author":"Townsend","year":"2022","journal-title":"J. Int. AIDS Soc."},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0030","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12879-021-05850-0","article-title":"Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naive patients infected with HIV-1: an update on a systematic review and network meta-analysis","volume":"21","author":"Nickel","year":"2021","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-022-00608-1","article-title":"A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection","volume":"19","author":"Zhao","year":"2022","journal-title":"Retrovirology"},{"issue":"16","key":"10.1016\/j.bcp.2023.115862_b0040","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 integrase inhibitors: A comparative review of efficacy and safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.bcp.2023.115862_b0045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02406-20","article-title":"Long dissociation of bictegravir from HIV-1 integrase-DNA complexes","volume":"65","author":"White","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.bcp.2023.115862_b0050","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.apsb.2021.11.009","article-title":"Approved HIV reverse transcriptase inhibitors in the past decade","volume":"14","author":"Li","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"9","key":"10.1016\/j.bcp.2023.115862_b0055","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00611-20","article-title":"HIV-1 integrase inhibitors that are active against drug-resistant integrase mutants","volume":"64","author":"Smith","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.bcp.2023.115862_b0060","doi-asserted-by":"crossref","first-page":"e1991","DOI":"10.1093\/cid\/ciaa1416","volume":"73","author":"Imaz","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2023.115862_b0065","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40121-021-00419-5","article-title":"Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged >\/= 65 Years: Week 48 Results of a Phase 3b","volume":"10","author":"Maggiolo","year":"2021","journal-title":"Open-Label Trial, Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/diagnostics12010076","article-title":"Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort","volume":"12","author":"Lazzaro","year":"2021","journal-title":"Diagnostics (basel)"},{"issue":"3","key":"10.1016\/j.bcp.2023.115862_b0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAI.0000000000002137","article-title":"Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B\/F\/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3","volume":"82","author":"Kityo","year":"2019","journal-title":"Noninferiority Trial, J Acquir Immune Defic Syndr"},{"issue":"12","key":"10.1016\/j.bcp.2023.115862_b0080","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1093\/jac\/dkab334","article-title":"Cerebrospinal fluid exposure to bictegravir\/emtricitabine\/tenofovir in HIV-1-infected patients with CNS impairment","volume":"76","author":"Gel\u00e9","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.bcp.2023.115862_b0085","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.bcp.2023.115862_b0090","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1093\/jac\/dkz412","article-title":"Erratum to: Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.bcp.2023.115862_b0095","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S2352-4642(21)00165-6","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2\/3 trial","volume":"5","author":"Gaur","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QAI.0000000000002731","article-title":"Switching to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b","volume":"88","author":"Hagins","year":"2021","journal-title":"Multicenter, Open-Label Study, J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.bcp.2023.115862_b0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/QAI.0000000000002789","article-title":"Brief Report: Efficacy and Safety of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials","volume":"88","author":"Orkin","year":"2021","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"4","key":"10.1016\/j.bcp.2023.115862_b0110","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"issue":"10107","key":"10.1016\/j.bcp.2023.115862_b0115","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"issue":"10107","key":"10.1016\/j.bcp.2023.115862_b0120","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bcp.2023.115862_b0125","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"issue":"7","key":"10.1016\/j.bcp.2023.115862_b0130","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.bcp.2023.115862_b0135","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bcp.2023.115862_b0140","article-title":"GS-US-380-1489 and GS-US-380-1490 study investigators, Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.bcp.2023.115862_b0145","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2023.115862_b0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.12833","article-title":"The potential role of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV","volume":"21","author":"Stellbrink","year":"2020","journal-title":"HIV Med."},{"issue":"6","key":"10.1016\/j.bcp.2023.115862_b0155","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"issue":"6","key":"10.1016\/j.bcp.2023.115862_b0160","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"issue":"6","key":"10.1016\/j.bcp.2023.115862_b0165","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.bcp.2023.115862_b0170","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/IDR.S331647","article-title":"Outcomes After Switching to BIC\/FTC\/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study","volume":"14","author":"Chang","year":"2021","journal-title":"Infect Drug Resist"},{"issue":"4","key":"10.1016\/j.bcp.2023.115862_b0175","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkab481","article-title":"Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre","volume":"77","author":"Ambrosioni","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"issue":"38","key":"10.1016\/j.bcp.2023.115862_b0180","doi-asserted-by":"crossref","first-page":"e27330","DOI":"10.1097\/MD.0000000000027330","article-title":"Real-world efficacy and safety of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in older people living with HIV","volume":"100","author":"Rolle","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.bcp.2023.115862_b0185","doi-asserted-by":"crossref","first-page":"512","DOI":"10.18683\/germs.2021.1286","article-title":"Treatment initiation or switch to BIC\/FTC\/TAF - real-world safety and efficacy data from two HIV centers in Romania","volume":"11","author":"S\u0103ndulescu","year":"2021","journal-title":"Germs"},{"issue":"3","key":"10.1016\/j.bcp.2023.115862_b0190","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s41669-022-00322-w","article-title":"Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Spain","volume":"6","author":"Estrada","year":"2022","journal-title":"PharmacoEcon. Open"},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0195","first-page":"ofaa625","article-title":"Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Treatment-Experienced Patients, Open Forum","volume":"8","author":"Schafer","year":"2021","journal-title":"Infect. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2023.115862_b0200","first-page":"111","article-title":"2022 update of the drug resistance mutations in HIV-1","volume":"30","author":"Wensing","year":"2022","journal-title":"Top Antivir Med"},{"issue":"2","key":"10.1016\/j.bcp.2023.115862_b0205","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.bcp.2023.115862_b0210","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/jac\/dkab115","article-title":"Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV-1 treatment-naive participants","volume":"76","author":"Acosta","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.bcp.2023.115862_b0215","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/QAI.0000000000002454","article-title":"Switching to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (B\/F\/TAF) From Dolutegravir (DTG)+F\/TAF or DTG+F\/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance","volume":"85","author":"Acosta","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bcp.2023.115862_b0220","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2022.11.012","article-title":"Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N\/R mutation","volume":"126","author":"Tsai","year":"2023","journal-title":"Int. J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.bcp.2023.115862_b0225","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/jmv.25564","article-title":"Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-na\u00efve individuals","volume":"91","author":"Margot","year":"2019","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0230","doi-asserted-by":"crossref","first-page":"e01717","DOI":"10.1128\/AAC.01717-19","article-title":"Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations","volume":"64","author":"Saladini","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.bcp.2023.115862_b0235","doi-asserted-by":"crossref","first-page":"e00014","DOI":"10.1128\/AAC.00014-19","article-title":"University of Washington-Dakar HIV-2 Study Group, Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants","volume":"63","author":"Smith","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2023.115862_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101412","article-title":"Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis","volume":"48","author":"Kanters","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0245","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41572-020-0181-1","article-title":"HIV and antiretroviral therapy-related fat alterations","volume":"6","author":"Koethe","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"6","key":"10.1016\/j.bcp.2023.115862_b0250","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.bcp.2023.115862_b0255","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/COH.0000000000000680","article-title":"Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV","volume":"16","author":"Lake","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"3","key":"10.1016\/j.bcp.2023.115862_b0260","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/cid\/ciz853","article-title":"Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women","volume":"71","author":"Kerchberger","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0265","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/QAD.0000000000003063","article-title":"Weight gain in treatment-naive HIV-1 infected patients starting abacavir\/lamivudine\/dolutegravir or tenofovir alafenamide\/emtricitabine\/bictegravir","volume":"36","author":"Calza","year":"2022","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0270","doi-asserted-by":"crossref","first-page":"88","DOI":"10.36469\/jheor.2021.2435","article-title":"Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide or Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: A Real-World Retrospective Study","volume":"8","author":"Emond","year":"2021","journal-title":"J Health Econ Outcomes Res"},{"issue":"2","key":"10.1016\/j.bcp.2023.115862_b0275","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/03007995.2021.2007006","article-title":"Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide or bictegravir\/emtricitabine\/tenofovir alafenamide in the United States","volume":"38","author":"Emond","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"issue":"9","key":"10.1016\/j.bcp.2023.115862_b0280","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2023.115862_b0285","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40262-014-0144-3","article-title":"Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins","volume":"53","author":"Regazzi","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.bcp.2023.115862_b0290","doi-asserted-by":"crossref","first-page":"e25844","DOI":"10.1002\/jia2.25844","article-title":"Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir\/emtricitabine\/tenofovir alafenamide","volume":"24","author":"Liou","year":"2021","journal-title":"J. Int. AIDS Soc."},{"issue":"7","key":"10.1016\/j.bcp.2023.115862_b0295","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(19)30154-7","article-title":"Management of active tuberculosis in adults with HIV","volume":"6","author":"Meintjes","year":"2019","journal-title":"Lancet HIV"},{"issue":"9","key":"10.1016\/j.bcp.2023.115862_b0300","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2352-3018(22)00160-6","article-title":"Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial","volume":"9","author":"Turkova","year":"2022","journal-title":"Lancet HIV"},{"issue":"11","key":"10.1016\/j.bcp.2023.115862_b0305","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/cid\/ciz1170","article-title":"Global Burden of Hepatitis B Infection in People Living With Human Immunodeficiency Virus: A Systematic Review and Meta-analysis","volume":"71","author":"Leumi","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0310","first-page":"14","article-title":"Chronic hepatitis B and HIV coinfection","volume":"31","author":"Corcorran","year":"2023","journal-title":"Top Antivir Med"},{"issue":"10","key":"10.1016\/j.bcp.2023.115862_b0315","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.bcp.2023.115862_b0320","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2019.04.007","article-title":"A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study","volume":"167","author":"Mandal","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2023.115862_b0325","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.603242","article-title":"Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments","volume":"11","author":"Perazzolo","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115862_b0330","doi-asserted-by":"crossref","first-page":"e02320","DOI":"10.1128\/AAC.02320-20","article-title":"A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis","volume":"65","author":"Mandal","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0335","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40121-020-00384-5","article-title":"Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review","volume":"10","author":"Fields","year":"2021","journal-title":"Infect. Dis. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2023.115862_b0340","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/apc.2021.0033","article-title":"Why Are Patients Switching from Tenofovir Disoproxil Fumarate\/Emtricitabine (Truvada) to Tenofovir Alafenamide\/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?","volume":"35","author":"D'Angelo","year":"2021","journal-title":"AIDS Patient Care STDS"},{"issue":"3","key":"10.1016\/j.bcp.2023.115862_b0345","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jac\/dkaa476","article-title":"Two-dose emtricitabine\/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection","volume":"76","author":"Bekerman","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/QAI.0000000000002912","article-title":"Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure","volume":"90","author":"Mayer","year":"2022","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"4","key":"10.1016\/j.bcp.2023.115862_b0355","first-page":"365","article-title":"Clinical pharmacology of the single tablet regimen bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF)","volume":"27","author":"Di Perri","year":"2019","journal-title":"Infez. Med."},{"issue":"4","key":"10.1016\/j.bcp.2023.115862_b0360","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/QAI.0000000000002765","article-title":"Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir\/Cobicistat in Treatment-Experienced Persons With HIV","volume":"88","author":"Salama","year":"2021","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"5","key":"10.1016\/j.bcp.2023.115862_b0365","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3390\/v12050564","article-title":"An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia","volume":"12","author":"Gong","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.bcp.2023.115862_b0370","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41596-021-00635-w","article-title":"Engineered human blood-brain barrier microfluidic model for vascular permeability analyses","volume":"17","author":"Hajal","year":"2022","journal-title":"Nat. Protoc."},{"issue":"10","key":"10.1016\/j.bcp.2023.115862_b0375","doi-asserted-by":"crossref","first-page":"2003937","DOI":"10.1002\/advs.202003937","article-title":"Development of Polymeric Nanoparticles for Blood-Brain Barrier Transfer-Strategies and Challenges","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv Sci (weinh)"},{"issue":"2","key":"10.1016\/j.bcp.2023.115862_b0380","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/febs.15438","article-title":"Close-up: HIV\/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms","volume":"288","author":"Engelman","year":"2021","journal-title":"FEBS J."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223004537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223004537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:37:14Z","timestamp":1736347034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223004537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":76,"alternative-id":["S0006295223004537"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115862","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biktarvy for the treatment of HIV infection: Progress and prospects","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115862"}}